Pharmena

Pharmena Liabilities

The The Liabilities of Pharmena (PHR.WA) as of Nov 6, 2026 is 1.27 M PLN. In the previous year, The Liabilities was 1.11 M PLN — a change of 15.10% (higher).

Liabilities

1.27 MPLN

YoY

15.10%

Last updated:

In 2025, Pharmena's total liabilities amounted to 1.27 M PLN, a 15.10% difference from the 1.11 M PLN total liabilities in the previous year.

The Pharmena Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
4.87 M PLN
Jan 1, 2019
6.74 M PLN
Jan 1, 2020
11.30 M PLN
Jan 1, 2021
16.27 M PLN
Jan 1, 2022
19.37 M PLN
Jan 1, 2023
1.91 M PLN
Jan 1, 2024
1.11 M PLN
Jan 1, 2025
1.27 M PLN
The Pharmena Liabilities history
YEARLiabilitiesYoY
1.27 MPLN+15.10%
1.11 MPLN-41.97%
1.91 MPLN-90.16%
19.37 MPLN+19.04%
16.27 MPLN+44.03%
11.30 MPLN+67.53%
6.74 MPLN+38.57%
4.87 MPLN-35.47%
7.54 MPLN-9.57%
8.34 MPLN+28.60%
6.49 MPLN+71.61%
3.78 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pharmena Stock analysis

What does Pharmena do? Pharmena SA develops and markets products based on 1-MNA, a patented physiological active substance. The company sells Dermena for hair loss, Dermena Plus for dandruff and hair loss, Accos for acne, Allerco for hypo-allergic body care, Thermi for burn and sunburn relief, and Revium for anti-wrinkle treatments. Pharmena collaborates with research centers in Europe, the US, and Canada on multidirectional studies. The company has a wholly owned subsidiary, Cortria Corporation, in the US, and its main shareholder is Pelion SA, with Polska Grupa Farmaceutyczna SA holding a 43.65% stake as of 2011. Pharmena SA's revenue comes from direct sales of its product lines to consumers and healthcare providers. Dermena and Dermena Plus target individuals with hair loss concerns, while Accos and Allerco appeal to those seeking acne and sensitive skin solutions. Thermi serves patients recovering from burns, and Revium attracts customers focused on anti-aging skincare. The company’s research partnerships with European, US, and Canadian institutions support product development and market positioning. The company operates through its subsidiary Cortria Corporation in the US, expanding its market reach. Polska Grupa Farmaceutyczna SA, a significant shareholder, likely influences strategic decisions. Pharmena’s product portfolio is structured around specific health and beauty segments, with Dermena and Revium targeting cosmetic and dermatological needs, and Thermi addressing medical recovery applications. Pharmena is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Pharmena's Liabilities

Pharmena's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Pharmena's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Pharmena's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Pharmena's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Pharmena’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Pharmena stock

The Liabilities of Pharmena is 1.27 M PLN in 2025.

The Liabilities of Pharmena changed from 1.11 M PLN to 1.27 M PLN, representing a 15.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Pharmena since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Pharmena historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Pharmena

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Pharmena